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Noninvasive diagnosis of pediatric nonalcoholic 
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Because nonalcoholic steatohepatitis can progress towards cirrhosis even in children, early detection 
of hepatic fibrosis and accurate diagnosis of nonalcoholic fatty liver disease (NAFLD) are important. 
Although liver biopsy is regarded as the gold standard of diagnosis, its clinical application is somewhat 
limited in children due to its invasiveness. Noninvasive diagnostic methods, including imaging studies, 
biomarkers of inflammation, oxidative stress, hepatic apoptosis, hepatic fibrosis, and noninvasive 
hepatic fibrosis scores have recently been developed for diagnosing the spectrum of NAFLD, 
particularly the severity of hepatic fibrosis. Although data and validation are still lacking for these 
noninvasive modalities in the pediatric population, these methods may be applicable for pediatric 
NAFLD. Therefore, noninvasive imaging studies, biomarkers, and hepatic fibrosis scoring systems may 
be useful in the detection of hepatic steatosis and the prediction of hepatic fibrosis, even in children 
with NAFLD.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is a form of chronic liver disease with hist­
opathologic features of typical alcohol­induced chronic liver disease that develops in 
individuals who do not consume alcohol excessively
1). Since Ludwig et al.
2) described 
nonalcoholic steatohepatitis (NASH) in 1980, there have been remarkable advances in 
diagnosing NAFLD. The disease spectrum of NAFLD ranges from simple steatosis to 
NASH, nonalcoholic hepatic fibrosis, and nonalcoholic cirrhosis, and NASH progresses 
towards cirrhosis, even in children
3­5). Therefore, early detection of hepatic fibrosis and 
accurate diagnosis of NAFLD are essential, and NASH, fibrosis, and cirrhosis should 
be distinguished from benign simple steatosis in obese children suspected to have NAFLD. 
Typically, the diagnosis of NASH is based on clinical exclusion of alcohol or drug 
intake, followed by serologic exclusion of other underlying liver diseases, and, finally, 
percutaneous liver biopsy. Percutaneous liver biopsy is regarded as the gold standard 
for diagnosing NAFLD, even in children, because a definite NAFLD diagnosis requires 
histological data such as macrovesicular steatosis, necroinflammation, and hepatic 
fibrosis
6). 
As Roberts
7) suggested in 2007, candidate criteria for liver biopsy in suspected 
pediatric NAFLD include factors such as an age of less than 10 years, hepatosplenomegaly, 
highly increased serum aminotransferase level, severe insulin resistance, comorbid 
chronic liver diseases, and family history. However, the use of liver biopsy is limited 
in the pediatric population because of its invasiveness and the fact that the histologic 
features of pediatric NASH are somewhat different from those of adult NASH
8,9).http://dx.doi.org/10.3345/kjp.2013.56.2.45
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Recently, noninvasive diagnostic methods, including imaging 
studies for detecting steatosis or fibrosis, and biomarkers of 
oxidative stress, inflammation, hepatocyte apoptosis, and hepatic 
fibrosis have been introduced to diagnose the spectrum of 
NAFLD
10,11). Additionally, noninvasive markers of hepatic fi­
brosis and noninvasive hepatic fibrosis scores have also been 
developed and applied for evaluating the severity of hepatic 
fibrosis, mainly in adults
12­14). 
To date, only a limited number of studies have examined 
noninvasive biochemical markers of hepatic fibrosis for pediatric 
NAFLD
15­17) and only a few studies have been performed on 
previously suggested fibrosis scores or NAFLD­related hepatic 
fibrosis scores in children
18­20). Although data and validation 
studies in the pediatric population are still lacking, these non­
invasive modalities can also be applied for pediatric NAFLD.
In this review, noninvasive clinical and laboratory parameters 
as possible clues of NAFLD, noninvasive imaging studies for 
detecting hepatic steatosis (and possibly fibrosis), newly de­
veloped noninvasive biomarkers for diagnosing NAFLD, and 
noninvasive hepatic fibrosis scores indicating the severity of 
hepatic fibrosis will be discussed, with a primary focus on 
pediatric NAFLD.
Clinical and laboratory clues to NAFLD in obese 
children
Most cases of NAFLD in obese children and adolescents 
are incidentally detected by health checkups at schools or 
hospitals. Most patients with NAFLD are asymptomatic, except 
for nonspecific clinical symptoms or signs such as easy fatig­
ability and right upper quadrant abdominal discomfort or 
hepatomegaly and acanthosis nigricans in some patients
21,22). 
There are no clinical features definitely indicative of NAFLD 
in obese children. However, some clinical features such as 
obstructive sleep apnea or acanthosis nigricans may be signifi­
cantly correlated with NAFLD
23). 
Increased levels of serum aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) in obese patients are well­
known predictors of NAFLD, particularly NASH, although serum 
aminotransferase levels sometimes remain within a normal 
range despite the presence of NAFLD
21). Mildly elevated levels 
of alkaline phosphatase or gamma glutamyl transpeptidase 
(GGT) have been associated with NAFLD
21). However, the levels 
of these enzymes do not reflect the severity of steatosis or hepatic 
fibrosis in patients with NAFLD.
According to a recent study on pediatric NASH
24), most NAFLD 
patients were obese children with a body mass index (BMI) 
higher than the 95th percentile, and other demographic fea­
tures were not significantly different among the 3 groups 
examined (no NASH, adult­type NASH, and definite NASH), 
although age and ethnicity differed between pediatric­type 
NASH and definite NASH. Increased levels of serum AST and 
GGT were significant predictors of NAFLD among the 3 groups, 
as were age, prothrombin time, and insulin resistance between 
2 groups
24). Additionally, increased serum AST levels, white 
blood cell count, and decreased hematocrit levels were found 
to be significant predictors of moderate fibrosis in that study
24). 
In contrast, a multicenter study in 2009 showed that none of 
the clinical features, including BMI or comorbid dis eases, were 
significantly correlated with the stage of fibrosis; laboratory 
markers were also not correlated, except for serum AST levels
25). 
The serum AST levels were correlated with the stage of fibrosis 
and could be used to distinguish significant fibrosis from no or 
mild fibrosis
25). However, in this study, the authors concluded 
that AST is a good predictor of severe fibrosis in children with 
NAFLD, based on the low value (0.63) obtained for the area 
under the receiver operating curve (AUROC)
25). In our recent 
studies, no single clinical or laboratory parameters reflected 
the presence or severity of hepatic fibrosis in children with 
NAFLD
18), except for BMI, which was significantly different 
among children with simple steatosis, type 1 adult NASH, and 
type 2 pediatric NASH
9).
Thus, noninvasive tools beyond clinical or laboratory markers 
are required to diagnose NAFLD in children, such as noninvasive 
imaging studies, biomarkers, or hepatic fibrosis scores.
Noninvasive imaging studies for pediatric NAFLD
Noninvasive imaging modalities for NAFLD include abdo minal 
ultrasonography (USG), abdominal computed tomography (CT), 
magnetic resonance imaging (MRI), fibroscan (hepatic ela­
sto graphy), magnetic resonance (MR) elastography, and MR 
spectroscopy
11).
Among noninvasive imaging techniques, abdominal USG 
has some advantages because it is a safe and economic modality 
showing a wide range of sensitivity and specificity in screening 
for the presence of hepatic steatosis in patients with NAFLD. 
Thus, abdominal USG is frequently used to detect the presence 
of fatty liver and to evaluate the degree of hepatic steatosis in 
the clinical field, although the diagnostic accuracy of liver USG 
in children has not yet been determined
26). Ultrasonographic 
criteria for assessing hepatic steatosis include hepatorenal 
echo contrast, liver brightness, intrahepatic vessel blurring, 
and visualization of the liver parenchyma and diaphragm
11). 
According to a recent study examining the clinical utility of 
ultrasonographic quantification of hepatic steatosis, liver USG 
is a useful tool for quantifying hepatic steatosis in children 
suspected to have NAFLD, because the degree of steatosis on 47 http://dx.doi.org/10.3345/kjp.2013.56.2.45
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USG was strongly correlated with the steatosis grade obtained 
on liver histopathological analysis
26). 
Unenhanced abdominal CT is useful for detecting the presence 
of fatty liver and visceral adiposity and sufficiently sensitive 
to quantify hepatic steatosis
27). The diagnostic accuracy of 
abdominal CT was relatively high in cases where hepatic steatosis 
was found to be present in more than 30% of the liver when a 
liver­spleen house field unit ratio was applied
28). However, CT 
is not recommended for the pediatric population due to the ra­
diation hazard.
Compared with abdominal CT, MRI is a highly accurate ima­
ging modality that is useful for identifying and quantifying 
hepatic steatosis safely, even in children, without radiation 
hazard
29). The disadvantages of using MRI for diagnosing 
NAFLD include high costs and limitations in patients with 
claustrophobia, metallic devices, or iron overload
30).
Clinically, abdominal USG, CT, and MRI have some limita­
tions because these methods cannot accurately differentiate 
between simple steatosis and NASH and cannot confirm the 
presence or stages of hepatic fibrosis
11). Recently introduced 
methods such as fibroscan, MR elastography, and MR spectros­
copy are promising modalities expected to overcome the limi­
tations of conventional imaging studies in detecting hepatic 
fibrosis or steatosis.
According to recent studies, fibroscan (transient elastography) 
using an ultrasonographic technique can be applied to nonin­
vasively detect liver fibrosis by measuring liver stiffness in 
both adults and children, although this method has some 
disadvantages, including decreased performance with increase 
in BMI and also expensive equipment
31,32). MR elastography, 
introduced for the assessment of hepatic fibrosis in adult 
patients with NAFLD, is a noninvasive imaging technique that 
can also be applied in children, despite some limitations
33,34). 
Additionally, 1H­MR spectroscopy may be an alternative 
noninvasive method for identifying and measuring hepatic fat 
content in patients with NAFLD
35). 
Regarding the noninvasive diagnosis of pediatric NAFLD by 
using imaging techniques, in 2012, the Hepatology Committee 
of European Society for Pediatric Gastroenterology, Hepatology, 
and Nutrition (ESPGHAN) concurred that most studies exami­
ning various imaging methods had been performed with 
adult NAFLD patients and that only a few studies had been 
performed for a large group of pediatric NAFLD patients
36). 
The committee reached a consensus in that abdominal USG 
is a safe method with a limited ability to quantify steatosis or 
fibrosis and that abdominal MRI is a very expensive, rapid, 
and reproducible method for measuring steatosis and fibrosis 
after some modifications
36). Fibroscan is not yet universally 
recommended for pediatric NAFLD
36).
Noninvasive biomarkers of NAFLD in children
The ideal biomarkers for NAFLD are those that would be 
simple and easy to measure, cost­effective, accurate in diag­
nosing NAFLD, capable of helping evaluate the stage of fibrosis 
and to monitor treatment response, and validated in a large or 
multicenter study
10). There are 4 major categories of noninva­
sive biomarkers that can be used to indicate NAFLD not only 
in adults but also in the pediatric population: hepatic inflam­
mation, oxidative stress, hepatocyte apoptosis, and hepatic 
fibrosis
10,11,23,36). 
1. Category I. Biomarkers of hepatic inflammation
Beyond laboratory markers of systemic inflammation such 
as C­reactive protein (CRP) or high sensitive CRP, cytokines 
have been suggested as possible biomarkers of hepatic inflam­
mation in both adults and children with NASH
10,23,36). Increased 
levels of serum tumor necrosis factor (TNF)­α and interleukin­ 
6, which are proinflammatory cytokines, were noted in patients 
with NAFLD, and increased levels of leptin and decreased levels 
of adiponectin, which are adipocytokines, are also reported to 
be related to NAFLD development in adults and children.
Controversy exists regarding the elevation of serum TNF­α 
levels in children with NAFLD: one study reported a correlation 
between serum TNF­α levels and NAFLD activity scores (NASs) 
obtained on liver biopsy
37), whereas other studies, including 
our recent study, reported no significant differences in serum 
TNF­α levels among different NAFLD groups
38). The serum 
concentration of leptin, an adipokine that is produced in adipose 
tissue and acts as a marker of insulin resistance, is also contro­
versial in pediatric NAFLD. This is because only a few studies 
have reported a correlation between serum leptin levels and 
the histological features of NAFLD or higher serum leptin levels 
in children with NAFLD than in controls
37,39), whereas other 
studies have reported no significant difference in serum leptin 
levels
40).
Adiponectin is also an adipokine and acts as a marker of 
insulin sensitivity. In some studies on pediatric NAFLD, serum 
adiponectin levels were found to decrease in obese children 
with elevated serum ALT levels and in obese children with 
fatty liver confirmed using USG
39,41). In our previous study on 
children with histopathologically confirmed NAFLD, serum 
adiponectin levels were lower in patients with NASH than in 
controls and patients with simple steatosis
40).
Recently, retinol­binding protein 4 (RBP4), which is an another 
adipocytokine associated with insulin resistance, was introduced 
as a possible noninvasive marker in children with NAFLD, 
indicating that circulating RBP4 is potentially related with the 
degree of liver damage in pediatric NAFLD
5,42).
These data suggest that measuring various biomarkers of http://dx.doi.org/10.3345/kjp.2013.56.2.45
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hepatic inflammation such as proinflammatory cytokines and 
adipocytokines may be useful for detecting NAFLD and for 
identifying NASH among the spectrum of NAFLD in children. 
However, to date, there is a lack of data to support the widespread 
clinical application of these cytokines for diagnosing NASH in 
children.
2. Category II. Biomarkers of oxidative stress
According to a 2­hit hypothesis as a possible mechanism 
for the pathogenesis of NAFLD
42), the first hit for developing 
NAFLD is the accumulation of macrovesicular fat in the liver, 
causing hepatic steatosis, and the second hit mainly includes 
oxidative stress producing excessive reactive oxidative species 
and free radicals via mitochondrial and peroxisomal pathways 
in the liver, thereby causing hepatocyte injury, inflammation, 
and fibrosis. Thus, measuring biomarkers of oxidative stress 
is expected to reflect NAFLD status; these biomarkers include 
lipid peroxidation products, antioxidant glutathione, or protein 
oxidation products
10). 
According to a recent study by Bell et al.
43), hepatic malon­
dialdehyde levels for hepatic lipid peroxidation were higher 
in children with biopsy­confirmed NAFLD than in controls 
or children with hepatitis C infection, although there was no 
significant difference between hepatic cytochrome P450 2E1 
protein levels in both groups. In a 2008 study, protein glutathi­
onylation, occurring as a response to oxidative stress, was 
found to have increased in the liver tissue of children with 
NAFLD; furthermore, it was found to be correlated with NASH 
and fibrosis
44). Nobili et al.
45) reported that oxidative stress 
parameters, including the levels of serum protein carbonyls, 
hepatic 8­hydroxy­2­deoxyguanosine, and circulating anti­
malondialdehyde adduct human serum albumin (anti­MDA­
HSA) immunoglobulin G antibody, were elevated in children 
with NAFLD and that anti­MDA­HSA levels correlated with 
NAS, reflecting the severity of NASH on liver biopsy. The results 
of these studies indicate that biomarkers of oxidative stress 
may be promising parameters for evaluating pediatric NAFLD, 
although these parameters remain controversial for adults
46). 
Further studies on clinically available serum biomarkers of 
oxidative stress are required.
3. Category III. Biomarkers of apoptosis
Recently, cytokeratin­18 (CK­18), which is a marker of hepato­
cyte apoptosis, has been regarded as the most promising bio­
marker for NASH. Some studies in adults and children have 
reported the role of CK­18 in differentiating NASH from benign 
simple steatosis
47­50). CK­18 levels were significantly higher in 
children with suspected NAFLD than in controls, indicating 
that CK­18 is the best single independent predictor of NAFLD in 
children
49). Even in biopsy­proven pediatric NAFLD, the level 
of the CK­18 fragment was higher in children with NAFLD 
than in controls
50). Moreover, the CK­18 levels were higher in 
children with NASH than in those with simple steatosis, and CK­
18 distinguished significant fibrosis from no or mild fibrosis in 
children
50). Therefore, CK­18, a biomarker of apoptosis, is a 
good predictor of NASH and hepatic fibrosis, even in the pe­
diatric population.
4. Category IV. Biomarkers of hepatic fibrosis
Ideal hepatic fibrosis biomarkers would be those that are liver­
specific and whose tests are easy to perform; the levels of these 
biomarkers would be minimally altered by biliary or urinary 
excretion or metabolism and would be reflective of hepatic 
fibrosis from any chronic liver injury, sufficiently sensitive to 
stratify stages of hepatic fibrosis, associated with progression 
or regression of hepatic fibrosis, and able to predict clinical 
outcome
13). Biomarkers of hepatic fibrosis or fibrogenesis have 
been suggested, including tumor growth factor­β (TGF­β), 
hyaluronic acid, laminin, type IV collagen, and other extra­
cellular matrix components, although there are some limitations 
to these mo lecules
10).
Among these biomarkers, serum TGF­β levels showed no 
significant relationship with stages of fibrosis according to 
histological results obtained for adults
51). 
A previous study on tissue inhibitor of metalloproteinase­1 
(TIMP­1) and hyaluronic acid showed that both serum TIMP­1 
and hyaluronic acid levels were significantly different in adult 
patients with NASH
52). In a pediatric study, hyaluronic acid 
levels of ≥1,200 ng/mL ruled out fibrosis (stage 0) and levels 
that were ≥2,100 ng/mL significantly distinguished advanced 
fibrosis (stage 2 or more) in children, indicating that hyaluronic 
acid may be a good predictor of hepatic fibrosis not only in 
adults but also in children
16).
Type IV collagen has been investigated only in adult patients 
with NASH and the results of a study suggested a weak but 
significant correlation between type IV collagen levels and 
stages of fibrosis; in this study, higher type IV collagen levels 
were seen in adults with advanced fibrosis (stage 3 or more) 
than in those with mild fibrosis
53). However, not much data 
are available regarding the application of type IV collagen for 
assessing hepatic fibrosis stages.
Thus, further studies are required to develop a single bio­
marker of hepatic fibrosis that can detect the presence of fibro­
sis and discriminate advanced fibrosis from no or mild fibrosis.
Noninvasive hepatic fibrosis scores of NAFLD in 
children
To date, a variety of noninvasive hepatic fibrosis scores, 49 http://dx.doi.org/10.3345/kjp.2013.56.2.45
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involving of one or more clinical parameters and laboratory 
markers, have been developed and applied in adults with 
NAFLD to differentiate NASH from benign simple steatosis, 
particularly in terms of the presence of hepatic fibrosis
14).
The AST/ALT ratio is a commonly used indicator of hepatic 
fibrosis because it is simple and easy to calculate; however, 
the diagnostic accuracy of an AST/ALT ratio>1 is very low in 
children with NAFLD, limiting its routine use as a hepatic fibrosis 
score
18,24). 
The AST­platelet ratio index (APRI), which includes AST 
and platelet count, has primarily been used to predict hepatic 
fibrosis in various chronic liver diseases in adults and children 
54,55). In our previous study on pediatric NAFLD, APRI was an 
excellent predictor of significant hepatic fibrosis (stage 2 or 
more) in children with biopsy­proven NASH
18).
FibroTest, which involves total bilirubin, GGT, α2­macroglo­
bulin, apolipoprotein A1, and haptoglobin levels, may be a 
good predictor of advanced fibrosis, but it has been evaluated 
only in adults with NAFLD and not in children
56).
The FIB­4 score, which involves age, AST, ALT levels, and 
platelet count, has been applied in adults with NAFLD and 
has been found to be a better noninvasive method of scoring 
fibrosis than other scores
57). In our recent study published in 
2012, FIB­4 was first evaluated in children with biopsy­confirmed 
NAFLD and showed the highest diagnostic accuracy among 
various noninvasive hepatic fibrosis scores in differentiating 
significant fibrosis (stage 2 or more) from no or mild fibrosis in 
pediatric NAFLD
18).
The enhanced liver fibrosis (ELF) test, involving hyaluronic 
acid, amino­terminal propeptide of type III collagen, and 
TIMP­1, was found to be a good predictor in adult patients with 
chronic liver disease
58), and was then also applied to children 
with NAFLD in order to predict hepatic fibrosis
19). The ELF test 
can differentiate significant fibrosis (stage 3 or more) from no 
or mild fibrosis, with an AUROC of 0.99 for a cutoff of 10.51 in 
children
19).
The pediatric NAFLD fibrosis index (PNFI) is the only nonin  ­
vasive hepatic fibrosis scoring system developed for children 
with NAFLD and involves age, waist circumference, and serum 
triglyceride levels
20). According to previous studies, PNFI is 
useful for differentiating children with hepatic fibrosis from 
those without fibrosis with an AUROC of 0.85 and 0.761, re­
spectively
20,59). On combining the PNFI and ELF tests, the 
AUROC for predicting hepatic fibrosis increased up to 0.944 in 
children
59).
Conclusion
Liver biopsy is regarded as the gold standard of diagnosis of 
NAFLD. However, the use of liver biopsy is clinically limited 
in children due to its invasiveness. Noninvasive diagnostic 
methods such as imaging studies, biomarkers of inflammation, 
oxidative stress, hepatic apoptosis, and hepatic fibrosis, and 
noninvasive hepatic fibrosis scores may be useful for overcoming 
these disadvantages.
Although these noninvasive methods have not been widely 
used or validated in pediatric NAFLD, some of them may be 
applicable for detecting hepatic steatosis and predicting hepatic 
fibrosis even in children with NAFLD. 
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